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Morphine-induced hyperalgesia and tolerance dramatically limit the use of morphine,
especially in chronic diseases. By definition, morphine tolerance is a reduced antinociceptive
effect for a given morphine dose, while morphine-induced hyperalgesia is a state of nociceptive
sensitization observed in morphine-treated patients.1,2 It is therefore tempting to postulate that
antinociceptive tolerance is set by the decrease in nociceptive threshold due to the hyperalgesia.3
However, this common view appears to be in contrast with clinical evidence indicating that while
increasing the morphine dose can effectively counteract morphine tolerance, the same approach
can backfire and worsen pain symptoms in patients with morphine-induced hyperalgesia.1 In our
recent study published in Nature Neuroscience,4 we demonstrated that morphine hyperalgesia and
morphine tolerance are mechanistically distinct and that morphine induces hyperalgesia by
recapitulating the same maladaptive mechanisms in the spinal cord observed in pathological pain
syndromes. 
In particular, we addressed the question whether microglia drive morphine-induced
hyperalgesia, as the communication between neurons and microglia in the spinal dorsal horn plays
a central role in the development of neuropathic pain.5 The role of microglia in diseases can be
tested by using pharmacological tools, such as minocycline, which have been proved to inhibit
microglia function.6 However, the specificity of such approaches to target microglia is debated and
direct effects on neuronal activity cannot be ruled out.7 Therefore, we decided to perform
intrathecal injections of a saporin-conjugated antibody against the (continued on page 6)
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Role of spinal microglia in the development of
morphine-induced hyperalgesia
Figure 1. Microglia depletion in the lumbar region of the spinal cord after intrathecal injections of  Mac-1-SAP.
Microglia are immunohistochemically identified by a mouse CD11b antibody, clone OX-42 (1:500). A) A
representative cervical spinal dorsal horn section obtained from a rat which was subcutaneously injected with
morphine for 10 days (10 mg/kg) and intrathecally injected with Mac-1-SAP (20 μg) during the last 3 days. B) A
representative lumbar spinal dorsal horn section from the same rat showing the decrease in OX-42 staining after
Mac-1-SAP treatment. Scale bar 50 μm.
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The Spring Brain Conference (SBC) will have its 25th Anniversary this March in
beautiful Sedona, Arizona. SBC is a broad-brush meeting in which neuroscientists
from all disciplines come to meet and exchange ideas in a beautiful environment.
The format is designed to allow for extensive discussion with people outside of your
immediate field. It is the objective of this conference to bring together scientists with
varied backgrounds, interests and approaches to the study of brain function to
promote the development of new strategies necessary to better understand the
complexities of neural systems. The confirmed speakers for the 2014 meeting offer a
fascinating look at what’s happening in the Neurosciences. 
The meeting starts Wednesday evening with a cocktail reception, introductions of
conference speakers and poster presenters and a surprise, very special, guest speaker
and entertainment that will kick off a splendid three days of science, learning,
conversation and fun, all in a beautiful location with golf, hiking, art galleries, and
museums.
The keynote speakers this year are impressive. On Thursday night, Baldomero Olivera, the discoverer of PriAlt
(Ziconotide), the conotoxin approved for cancer pain, will discuss his fabulous stories of the myriad of toxins from animals that
build gorgeous sea shells. On Friday night, Michael Merzenich (UCSF) will provide the Keynote Address. Dr. Merzenich was
honored by election into the National Academy of Sciences for his research on brain plasticity. 
On Thursday, Friday, and Saturday, the morning sessions begin at 8am and include the following highlights: Howard
Eichenbaum, will give a special talk on his fundamental work on Learning and Memory; Stem Cells in the Clinic with Hans
Keirstead, who began the first stem cell clinical trial, as Session Leader; Pain and the Brain (Frank Porreca, Session Leader,
has invited Allan Basbaum and Rob Caudle to present the latest in the pain field; Somatosensory Issues with Mark A. Hoon,
Session Leader, NIH -- check out Dr. Hoon’s recent publication in Science on itch and how it works); Songbirds and Vocal
Learning with Stephanie White, UCLA, as Session Leader, and what these birds tell us about song and speech, synapses, and
even disorders such as autism.
Interspersed in the sessions will be poster presenters with short presentations and Q&A. If you have a poster you’d like to
share (maybe a poster presented at SFN), please send a message at the Spring Brain website (www.SpringBrain.org) or stop by
the ATS Booth at the Society for Neuroscience meeting in San Diego (November 9-13; Booth 1120).
Congratulations,
Mr. and Mrs. Brian Russell !
Spring Brain Conference: 25th Anniversary
March 19-22, 2014
ATS is pleased to announce the marriage of Brian Russell to
Candilee DeBlase. The happy couple celebrated their nuptials
on Saturday, October 5. 
Brian is Asst. Research Scientist, Custom Services Guru and
Product Manager and has been making great contributions to
ATS since October 2000.
Brian and Candi, we wish you both all the best!
Come to the Spring Brain Conference 25th Anniversary Social in San Diego
DATE: Sunday, November 10 at the Hilton Gaslamp Hotel (directly across from the San Diego Convention Center)
TIME:  5pm - 7pm
WHAT: Live music, appetizers, beverages: come learn more about SBC and celebrate 25 years of learning!
Email denise@springbrain.org for your free drink ticket and invitation.
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P2Y1 receptors expressed by C1
neurons determine peripheral
chemoreceptor modulation of
breathing, sympathetic activity, and
blood pressure.
Wenker IC, Sobrinho CR, Takakura AC,
Mulkey DK, Moreira TS. 
Hypertension 62(2):263-273, 2013. 
Peripheral chemoreceptor activation
response is mediated by
catecholaminergic C1 cells in the rostral
ventrolateral medulla (RVLM). The
authors investigated the molecular
mechanisms linking this drive to
increased sympathetic activity and
hypertension through a variety of
methods, including lesioning C1 cells in
the RVLM. Rats received 4.2-ng bilateral
injections of Anti-DBH-SAP (Cat. 
#IT-03) into the RVLM. Comparison of
lesioned animals to controls
demonstrated that P2Y1 receptors on C1
cells in the RVLM are key components
in the regulation of breathing,
sympathetic nerve activity, and blood
pressure.
GABAergic Terminals Are a Source of
Galanin to Modulate Cholinergic
Neuron Development in the Neonatal
Forebrain.
Keimpema E, Zheng K, Barde SS, Berghuis
P, Dobszay MB, Schnell R, Mulder J, Luiten
PG, Xu ZD, Runesson J, Langel U, Lu B,
Hokfelt T, Harkany T. 
Cereb Cortex Epub2013. 
In this work the authors sought to clarify
the role of galanin during brain
development. Several different
techniques were used including the use
of Galanin-SAP (Cat. #IT-34) on primary
cell cultures from the fetal forebrains of
rats. Cultured basal forebrain neurons
were exposed to 5 ng/ml of Galanin-SAP
for 8 hours, and cell death was assessed
after 72 hours. Cholinergic cells were
killed by Galanin-SAP, indicating that
these neurons can use extracellular
galanin-2 receptors to facilitate
development.
Medial Septal Cholinergic Neurons
Modulate Isoflurane Anesthesia.
Tai SK, Ma J, Leung LS. 
Anesthesiology Epub2013. 
General anesthesia is associated with a
decrease in cholinergic function. This
work examines the effect of volatile
anesthetics such as isoflurane or
ketamine in the context of cholinergic
depletion. Rats received 105-ng bilateral
injections of 192-IgG-SAP (Cat. #IT-01)
into the medial septum. Anesthetic
effects were evaluated using a loss of
righting reflex test. There was no
difference between lesioned and control
groups in the response to ketamine.
When treated with isoflurane, lesioned
animals were affected for longer periods
of time, and hippocampal response was
reduced. The results suggest a role for
septal cholinergic neurons in the
sensitivity to isoflurane.
Epitopes of the Highly Immunogenic
Trichomonas vaginalis alpha-Actinin
Are Serodiagnostic Targets for Both
Women and Men.
Neace CJ, Alderete JF. 
J Clin Microbiol 51(8):2483-2490, 2013. 
Trichomonas vaginalis is an anaerobic
protozoan that is the most common
nonviral causative agent for sexually-
transmitted infections. The presence of T.
vaginalis in men is usually
asymptomatic, making it difficult to
assess exposure to the organism. The
authors examined sera from exposed
individuals for reactivity to specific
epitopes of trichomonad α-actinin. A
recombinant version of trichonomad α-
actinin was constructed and detected
using Anti-6His (Cat. #AB-213). Some
epitopes were reactive with sera from
both men and women, making them
potential diagnostic targets.
Targeting Topics: Recent Scientific References
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Reviewed by Matthew Kohls
Neurotrophic factors rescue basal
forebrain cholinergic neurons and
improveperformance on a spatial
learning test.
Lee YS, Danandeh A, Baratta J, Lin CY, Yu
J, Robertson RT.
Exp Neurol Epub2013. 
It is thought that therapeutic treatments
of the cholinergic system may be a
viable treatment for Alzheimer’s disease.
In order to examine this hypothesis the
authors administered a total of 160 ng of
192-IgG-SAP (Cat. #IT-01) in the form
of bilateral injections into the medial
septum. The lesioned animals then
received 4-week infusions of nerve
growth factor, neurotrophin 3, or both
into the lateral ventricles. Animals
treated with any neurotrophin, either
alone or as a combination, retained more
ChAT-positive neurons and performed
better on a delayed match-to-position
task than control animals. The data
strengthen the theory that exogenous
neurotrophic factors ameliorate the
effects of Alzheimer’s disease.
Neurotrophin receptor p75 mediates
the uptake of the amyloid beta
(Abeta) peptide, guiding it to
lysosomes for degradation in basal
forebrain cholinergic neurons.
Ovsepian SV, Antyborzec I, O’Leary VB,
Zaborszky L, Herms J, Oliver Dolly J. 
Brain Struct Funct Epub2013. 
Accumulation of β-amyloid in the brain
is considered one of the main causes of
Alzheimer’s disease. The increase in β-
amyloid is accompanied by a reduction
in levels of the high affinity nerve
growth factor receptor (trkA) and
cognitive impairment. The authors
looked at levels of the low affinity nerve
growth factor receptor (p75) that do not
decline. Using a 0.8-μg injection of 192-
Cy3 (Cat. #FL-01) into the medial
prefrontal cortex of rats the authors
assessed the transport of p75 and β-
amyloid by microscopy. The results
indicate that the primary destinations of
both p75 and β-amyloid were the late
endosome and lysosome.
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Leptin-sensitive neurons in the
arcuate nucleus integrate activity and
temperature circadian rhythms and
anticipatory responses to food
restriction.
Wiater MF, Li AJ, Dinh TT, Jansen HT,
Ritter S. 
Am J Physiol Regul Integr Comp Physiol
Epub2013. 
The arcuate nucleus (Arc) of the
hypothalamus is known to participate in
the regulation of feeding, adiposity, and
leptin-dependent metabolism. The
authors examined the role of leptin-
receptive neurons in locomotor and
temperature rhythms. Rats received four
bilateral injections of Leptin-SAP (Cat.
#IT-47) into the Arc; Blank-SAP (Cat.
#IT-21) was used as a control. The
lesion affected learning connected to
light cycles, but not learning connected
to food schedules, suggesting a
mechanism for internal desynchrony that
might play a role in obesity and other
metabolic disorders.
C1 neurons: the body’s EMTs.
Guyenet PG, Stornetta RL, Bochorishvili G,
Depuy SD, Burke PG, Abbott SB. 
Am J Physiol Regul Integr Comp Physiol
305(3):R187-204, 2013. 
Although mainly known for their
involvement in the control of arterial
pressure, C1 neurons are also suspected
to participate in numerous other
physiological processes such as
neuroendocrine response, glucose
homeostasis, food consumption, and
others. This review discusses the role of
these neurons as ‘emergency medical
technicians’ – cells that produce and
modulate physiological survival
responses to acute physical stress. The
use of Anti-DBH-SAP (Cat. #IT-03) to
delineate C1 neurons in the rostral
ventrolateral aspect of the medulla
oblongata is discussed.
(continued from page 3)
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Loss of neurons in rostral
ventromedial medulla that express
neurokinin-1 receptors decreases the
development of hyperalgesia.
Khasabov SG, Simone DA. 
Neuroscience 250C:151-165, 2013. 
Previous data has indicated that
neurokinin-1 receptors are located on ON
cells in the rostral ventromedial medulla
(RVM). ON cells are considered
pronociceptive because noxious
stimulation is stimulatory. In this work
the authors eliminated ON cells using
0.3-μl injections of 1 μM SSP-SAP (Cat.
#IT-11) into the left and right side of the
RVM. Blank-SAP (Cat. #IT-21) was used
as a control. SSP-SAP treatment did not
change mechanical or heat withdrawal
responses, or change morphine-induced
analgesia. A significant reduction in the
duration of nocifensive behaviors
induced by various hyperalgesic
stimulators indicated that these neurons
are involved in pain facilitation rather
than modulation.
Selective Immunotoxic Lesions of
Basal Forebrain Cholinergic Neurons:
Twenty Years of Research and New
Directions.
Baxter MG, Bucci DJ. 
Behav Neurosci Epub2013. 
This review covers twenty years of basal
forebrain cholinergic lesioning. The
initial use of 192-IgG-SAP (Cat. #IT-01)
is discussed, as well as other
immunotoxins such as GAT-1-SAP (Cat.
#IT-32) and OX7-SAP (Cat. #IT-02). The
findings generated by the use of 192-
IgG-SAP and how those data have
helped forward the understanding of how
the cholinergic system functions in the
basal forebrain are detailed. The authors
also discuss new directions in the field.
Noggin and Sonic hedgehog are
involved in compensatory changes
within the motoneuron-depleted
mouse spinal cord.
Gulino R, Gulisano M. 
J Neurol Sci 332(1-2):102-109, 2013. 
Noggin (NOG) and Sonic hedgehog
(Shh) are both involved in the generation
and organization of neural tissues. In
order to clarify the role of these two
proteins in the regulation of neurogenesis
and/or neuroplasticity the authors used a
motoneuron depletion model in the
mouse spinal cord. 3 μg of CTB-SAP
(Cat. #IT-14) was injected into each of
the medial and lateral gastrocnemius
muscles and the expression of NOG and
Shh were monitored. Motor performance
also correlated with NOG and Shh
levels, indicating that these proteins
could play roles in regeneration and
functional restoration.
Cortical Metabolic Deficits in a Rat
Model of Cholinergic Basal Forebrain
Degeneration.
Gelfo F, Petrosini L, Graziano A, De Bartolo
P, Burello L, Vitale E, Polverino A, Iuliano
A, Sorrentino G, Mandolesi L. 
Neurochem Res Epub2013. 
In this work the authors investigated the
connection between cholinergic
depletion caused by conditions such as
Alzheimer’s disease and cerebral energy
metabolism deficits. Rats received a 
0.4-μg injection of 192-IgG-SAP (Cat. 
#IT-01) into the nucleus basalis
magnocellularis. Neuronal metabolic
activity was measured by assaying
cytochrome oxidase (CO) activity. The
unilateral injection produced a bilateral
deficit in CO activity throughout the
cortex, and the front and parietal cortices
showed CO deficits before the lesion
was complete. The data suggest a link
between cholinergic hypofunctionality
and metabolic deficit.
Don’t see your publication here?
Send us a PDF at ats@ATSbio.com 
and we’ll be sure to review it in the
next issue of Targeting Trends.
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Q:  We have a publication in review and put this statement in the paper, “The
mouse monoclonal antibody to the low affinity nerve growth factor receptor
(p75NTR; Advanced Targeting Systems) was derived from immunization of mice with
WM245 melanoma cells and recognizes p75NTR in human, primate, rabbit, sheep,
dog, cat, and pig. According to the manufacturer’s information, the antibody was
tested by flow cytometry.” One of the reviewers wants to know more about the flow
cytometry used to characterize this antibody (Cat. #AB-N07). Can you help,
please?
A:  This antibody is routinely tested by flow cytometry. The quality control flow
data can be found on the data sheet on our website. HS294T cells, human
metastatic melanoma cells, were used in flow cytometry with Anti-p75NTR
(ME20.4, Cat. #AB-N07).
Cells were treated with 
4 µg of AB-N07 and subsequently with Anti-murine IgG-FITC
(Cat. #FL-07). This assay shows the binding affinity of AB-N07
to cells known to express p75NTR.
Q:  Does AB-T183 (Lauric Acid Rat Polyclonal, Conjugated) recognize lauric acid alone, or does it need to be conjugated to
something (a protein carrier)? 
A:  This antibody targets conjugated Lauric Acid. It does not recognize free lauric acid. Antisera was preabsorbed on protein
carriers and ammonium sulfate-purified. Using a conjugate Lauric acid-Gluteraldehyde-Protein Carrier (PC), antibody
specificity was performed with an ELISA test by competition experiments with the following compounds:
Compounds Cross-Reactivity Ratios
Lauric acid-PC 1
Caprylic acid-PC 1/300
Myristic acid-PC 1/400
Palmitic acid-PC 1/>50,000
Caproic acid-PC 1/>50,000
Oleic acid-PC 1/>50,000
Usage: Applications include immunohistochemistry (1/500-1/2,000) and immunocytochemistry.
Controls: Lauric Acid, conjugated, Cat. #AG-183
Q&A Products
anti-p75NTR (AB-N07)
Lauric Acid Polyclonal, conjugated (AB-T183)
Targeting Talk: Product Questions
Send a message on our
website
to get answers to 
your targeting questions.
Implication of Cerebral Dopamine-
beta Hydroxylase for Cardiovascular
and Mood Regulation in Rats.
Chang ST, Liu YP, Huang CL, Wang PY,
Tung CS. 
Chin J Physiol 56(4)2013. 
The ascending fibers affected by
norepinephrine are involved in a variety
of processes, including emotion, anxiety,
and regulation of central autonomic
outflows such as cardiovascular
regulation and energy balance. The
authors examined whether the loss of
norephinephrine would cause
autonomic failure in cardiovascular
regulation. Rats received a single
intraventricular injection of anti-
DBH-SAP (Cat. #IT-03). Saporin
(Cat. #PR-01) was used as a control.
The results demonstrate that
norepinephrine deficits in the brain
influence reduction of excitatory
responses to orthostatic stress.
Targeting Topics: Recent Scientific References
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macrophage-1 antigen (Mac-1, 16–32 μg; Mac-1-SAP rat, Cat
#IT-33) to selectively ablate spinal microglia in rats with
established morphine-induced hyperalgesia. Injections of Mac-
1-SAP or saporin alone as control (SAP, 20 μg; Cat #PR-01)
were initiated after seven days of morphine treatment and
performed at lumbar level once a day for three days. Mac-1-
SAP significantly reduced the level of CD11b expression in
the lumbar spinal dorsal horn (see Fig.1) and the treatment
reversed mechanical and thermal hypersensitivity induced by
morphine. Conversely, the immunotoxin did not affect the
development of morphine tolerance in the same animals.
These findings point out the specific role of microglia in
the development of pain hypersensitivity following morphine
treatment. Thereafter, we dissected the underlying molecular
mechanisms and found that morphine induced P2X4 receptor
upregulation in spinal microglia, which in turn triggered the
synthesis and release of brain-derived neurotrophic factor
(BDNF). Microglial BDNF has been shown to induce pain
hypersensitivity in spinal neurons by hampering the function
of the K+-Cl- co-transporter KCC2, the main neuronal chloride
extruding transporter in neurons, via trkB signaling.5
Consistently, we found that such BDNF-trkB-KCC2 signaling
cascade is activated by morphine and alters chloride-mediated
inhibition on spinal neurons, thus increasing network
excitability. 
All together, our study indicates that morphine-induced
hyperalgesia, as neuropathic pain, is a pathological alteration
of pain sensitivity whose expression is gated by spinal
microglia. Targeting at any level, this microglia-to-neuron
cascade is a valuable strategy to improve the use of morphine
in chronic pain.
References
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Solve this quarter’s teaser at
www.ATSbio.com/news/13q4_teaser.html.
WINNERS: Maria Kot, Inst of Pharmacology, PAS, Krakow, Poland;
Rene Schweickhardt, EMD Serono, Billerica, MA; Prasanthi Geda,
Merck, Boston, MA; Shunsuke Takasuga, Akita University, Akita-shi,
Japan; Judene Bliss, Roswell Park Cancer Inst, Buffalo, NY; 
Terry Beltz, Univ Iowa, Iowa City, IA; Richard Fuerstenberg, R&D
Systems, Minneapolis, MN; Jheem Medh, California State Univ,
Northridge, CA; Adam Farmer, Triangle Research Labs, Research
Triangle Park, NC; Shelle Malkmus, University of California, San
Diego, CA; Sherie Ma, Florey Inst of Neuroscience and Mental
Health, Parkville, Australia; Clay Archer, University of California,
San Diego, CA; Glenn Kageyama, Cal Poly University, Pomona, CA; 
Bob Speth, Nova Southeastern Univ, Fort Lauderdale, FL
The solution to the puzzle was:
Jumbles:
PLURIPOTENT
HEDGEHOG
DORSAL
GANGLIONIC
EMBRYONIC
What the ATS Knockout
Mouse did to support
himself while earning his PhD in
Neuroscience. 
Answer:  
HE WORKED AS A  ... MODEL.
Congratulations to the puzzle solvers from last quarter. 
Each winner received a Knockout Mouse Tote Bag.
Targeting Teaser Solution
Bob Speth with his
showing off his prize.
Photo courtesy of
Eduardo Carrera.
Screening large numbers of antibodies for the ability to internalize
can be prohibitively expensive in both cost and time. The ZAP
Antibody Internalization Kit contains all the components needed for
three 96-well plates, or 288 tests. The ability to perform a diagnostic
screen that is amenable to high-throughput methods, prior to direct
conjugation of those antibodies, is a great cost-benefit in the
development of an effective targeted conjugate. Targeted conjugates are
widely used to escort payloads to specific cell populations in vitro and
in vivo for both basic research and pharmaceutical development. The
development of an effective and specific targeted conjugate is a long
and costly process. A molecule that targets the marker of choice (a
Targeting Agent) must be identified and produced; internalization and
specificity must be verified and characterized. Desirable traits of a
Targeting Agent (TA) include high specificity and rapid internalization. The TA can be an antibody, peptide, protein, or any other
molecule that recognizes a cell-surface marker. Antibodies often make the best targeting agents, and the choice of the correct
antibody is crucial to the specificity and performance of payload delivery. 
The ZAP products produced by Advanced Targeting Systems, Inc. allow a
large number of antibodies to be screened quickly and cost-effectively for
specificity, functional binding, internalization, and EC50 determination. The
wide selection of these secondary conjugates identified by the ZAP moniker
provide ideal tools for screening potential antibodies (Fig 1). They are
constructed using either species-specific polyclonal anti-IgG antibodies, or
streptavidin (alternate kit for use with biotinylated targeting agents), that are
chemically attached to Saporin, the most potent of the plant ribosome-
inactivating proteins. The mechanism of action of ZAP-based conjugates is
detailed in Fig 2.
Use of a ZAP conjugate eliminates the time-consuming and expensive step
of conjugating each TA candidate to the payload: the ZAP product can simply
be added to cells together with the TA candidate. Once the materials have been
administered, the antibody directs the ZAP to the cells of interest, the complex
is bound by the targeted cells, internalized, and the Saporin protein is released
within the cytosol to inactivate the ribosomes. Cells not expressing the target do not bind or internalize the ZAP-antibody
complex, and are not affected. Saporin has no binding chain, and no means of getting into cells on its own. 
The ZAP Antibody Internalization Kit contains all of the materials needed to screen your antibody.  Included, in addition to
the selected ZAP products, are controls and developing reagents for the assay.  All the user provides are the materials specific to
their experiment (the antibody candidate, cells expressing the target, and culture
reagents). Recommended protocols for use are detailed in a booklet and on a
flash drive provided, and are
specific to the particular kit
chosen (Whole-ZAP, Fab-
ZAP, or FabFc-ZAP).
Examples of predicted assay
results are also included for
comparison; a successful
assay provides an EC50 useful
in determining if the
candidate-antibody should be
pursued at the next level.
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“I’m not
sleeping. I’m
meditating.”
ZAP Antibody Internalization Kit (Cat. #KIT-100)
Targeting Tools: Featured Products Contributed by Brian Russell, Product Manager
Fig 2
Fig 1
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“Molecular Surgery for Scientists”
Toll-Free: (877) 889-2288
Phone: (858) 642-1988
Fax: (858) 642-1989
Targeting Technology
Advanced Targeting Systems’ technology -
Molecular Neurosurgery - is a 
modification of one of the most widely
used techniques: surgical lesioning of a
region and observation of the effect.
The targeting agent is administered to the
cells (in vivo or in vitro).
The
antibody
seeks out
its target
receptor
on the cell
surface.
Cells that
do not
have the
receptor
will not be
affected.
The conjugate is internalized and
SAPORIN breaks away from the antibody.
SAPORIN
inactivates the
ribosomes.  
The result is
CELL DEATH.
Targeting Teaser
Choose an
ANTIBODY§
specific to
your cell
type.
SAPORIN
is a potent
cytotoxin.
Safe in the
lab. Lethal
in the cell.  
ATS binds SAPORIN with your
ANTIBODY to make a 
powerful targeting agent.
§ or anything recognized on the 
cell surface and internalized.
WIN! SOLVE the puzzle online with the
correct solution by 
December 31, 2013.
WIN a large, reusable flat-bottom
tote bag featuring the 25th
Annual Spring Brain Conference!
www.atsbio.com/news/13q4_teaser.html
Unscramble these five Jumbles taken from the cover story, one letter
to each block, to solve the puzzle.
ANSWER:
!IF I ONLY HAD . . .
Arrange the circled letters to form the
answer, as suggested by the above clue.
UNSCORENIECE
PROMINHE
HERICOLD
FARCEKIB
STORRENTRAP What the scarecrow ‘thought’ he
needed to become a neuroscientist.
